Archive

Neovasc to Participate at Upcoming Investor and Medical Conferences in February

NASDAQ: NVCNTSX: NVC VANCOUVER, Feb. 9, 2015 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVC) today announced that the Company will be participating at three upcoming conferences. 2015 Leerink Global Healthcare ConferenceWaldorf Astoria, New YorkWednesday, February 11, 2015 at 10:40 am ET Neovasc...

Read More

Neovasc closes offering of common shares

NASDAQ: NVCNTSX: NVC VANCOUVER, Feb. 3, 2015 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVC) is pleased to announce the closing of its previously announced underwritten public offering of 12,075,000 common shares of the Company at a price per share of US$7.19 (the "Offering")...

Read More

Neovasc increases size and prices offering of common shares

NASDAQ: NVCNTSX: NVC VANCOUVER, Jan. 29, 2015 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVC) is pleased to announce that due to market interest, it has increased the size of its previously announced underwritten public offering from 8,000,000 common shares to 10,500,000 common...

Read More

Neovasc Announces Proposed Public Offering of Common Shares

NASDAQ: NVCN TSX: NVC VANCOUVER, Jan. 26, 2015 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVC) today announced that it has commenced an underwritten public offering in the United States of 8,000,000 common shares of the Company, consisting of 6,340,000 common shares to be...

Read More

Neovasc to Ring Closing Bell at Nasdaq

NASDAQ: NVCNTSX: NVC   VANCOUVER, Jan. 13, 2015 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVC) today announced it will visit the Nasdaq MarketSite in Times Square in celebration of its Nasdaq listing. Neovasc is focused on revolutionizing how advanced heart disease is...

Read More

Neovasc Announces Treatment of First Patient in TIARA-I Clinical Trial

NASDAQ: NVCNTSX: NVC VANCOUVER, Dec. 1, 2014 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVC) today announced that the first patient has been enrolled in the European arm of its TIARA-I Early Feasibility Trial, a multinational, multicenter trial being conducted at centers...

Read More

Neovasc Inc. Announces Financial Results For The Third Quarter 2014

--Tiara receives conditional approval from FDA for Early Feasibility Study-- --Reducer Live Case completed successfully at TCT 2014--    NASDAQ: NVCNTSX: NVC VANCOUVER, Nov. 13, 2014 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVC) today announced financial results for the three and nine months...

Read More